---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-036397"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:38:08.296721+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vir Biotechnology Q3 net loss $163.4M; revenue down 99% YoY on sotrovimab sales decline

## Summary
- Net loss of $163.4M ($1.22/share) vs net income of $175.3M ($1.32/share) in Q3 2022.
- Total revenue $2.6M, down 99.3% from $374.6M a year ago due to lower sotrovimab sales.
- Cash, equivalents and investments $1.7B; $67M paid to GSK for excess sotrovimab supply.
- Secured ~$50M in new BARDA funding to advance next-gen COVID-19 mAb VIR-7229 through Phase 1.
- Appointed Jennifer Towne, Ph.D., as EVP and Chief Scientific Officer, effective Nov 6, 2023.

## SEC filing metadata
- accession: 0001628280-23-036397
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000162828023036397/0001628280-23-036397-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000162828023036397/vir-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-036397
- JSON: https://secwatch.observer/filing/0001628280-23-036397.json
- Plain text: https://secwatch.observer/filing/0001628280-23-036397.txt

## Key facts
- Earnings Releases
  Vir Biotechnology, Inc. reported third quarter ended September 30, 2023 results: revenue $2.6 million.
  - Period: third quarter ended September 30, 2023
  - Revenue: $2.6 million
  - Result: reported results
  source text: Total revenues for the quarter ended September 30, 2023, were $2.6 million compared to $374.6 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000162828023036397/0001628280-23-036397-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.